Erica D Warlick

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Onco Targets Ther 3:157-65. 2010
  2. ncbi request reprint Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 20:202-8. 2014
  3. doi request reprint Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:480-6. 2012
  4. pmc Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
    Erica Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 119:4083-90. 2012
  5. doi request reprint Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
  6. doi request reprint Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
  7. ncbi request reprint Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
  8. doi request reprint Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
  9. doi request reprint Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011
  10. ncbi request reprint Allotransplantation for patients age ≥40 years with non-hodgkin lymphoma: encouraging progression-free survival
    Brian L McClune
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    Biol Blood Marrow Transplant 20:960-8. 2014

Detail Information

Publications10

  1. pmc Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Onco Targets Ther 3:157-65. 2010
    ..This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS...
  2. ncbi request reprint Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota Electronic address
    Biol Blood Marrow Transplant 20:202-8. 2014
    ..If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required. ..
  3. doi request reprint Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation
    Erica D Warlick
    Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 18:480-6. 2012
    ..The lower DLI dose regimen improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD...
  4. pmc Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
    Erica Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 119:4083-90. 2012
    ..Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1...
  5. doi request reprint Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    Erica D Warlick
    Blood and Marrow Transplant Program, Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:30-8. 2009
    ....
  6. doi request reprint Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Erica D Warlick
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Leuk Lymphoma 52:2045-9. 2011
    ..We review the current literature regarding natural killer (NK) cell, T cell, and myeloid derived suppressor cell abnormalities in the spectrum of MDS...
  7. ncbi request reprint Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas
    Erica D Warlick
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 17:1025-32. 2011
    ....
  8. doi request reprint Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions
    Erica D Warlick
    Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota, USA
    Curr Opin Oncol 22:150-4. 2010
    ..This review highlights strategies to optimize transplant for MDS and identifies unresolved questions...
  9. doi request reprint Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
    Steven E McCormack
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Res 35:757-61. 2011
    ..Our data suggest that exposure to consolidation chemotherapy prior to RIC HCT may not improve post-transplant outcomes for patients with AML in CR1...
  10. ncbi request reprint Allotransplantation for patients age ≥40 years with non-hodgkin lymphoma: encouraging progression-free survival
    Brian L McClune
    Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
    Biol Blood Marrow Transplant 20:960-8. 2014
    ..Even for patients age ≥55 years, OS still approached 40% at 3 years, suggesting that HCT affects long-term remission and remains underused in qualified older patients with NHL. ..